Purdue-developed nanomaterial significantly enhances potential COVID-19 therapeutic

Pure niclosamide (left) clouds a solution, and the crystalline structure of the drug prevents absorption. OHPP-developed niclosamide (right), created by Purdue’s Yuan Yao, is over 5,000 times more soluble. Solubility could be key to niclosamide being an effective drug against the SARS-CoV-2 virus causing the COVID-19 pandemic. (Photo courtesy of Elsevier) Pure niclosamide (left) clouds a solution, and the crystalline structure of the drug prevents absorption. OHPP-developed niclosamide (right), created by Purdue’s Yuan Yao, is over 5,000 times more soluble. Solubility could be key to niclosamide being an effective drug against the SARS-CoV-2 virus causing the COVID-19 pandemic. (Photo courtesy of Elsevier)

Niclosamide, a drug used to treat tapeworms, has been found to have strong antiviral effect against SARS-CoV-2, the virus causing the COVID-19 pandemic. But the drug itself has limited potential because its structure makes it difficult to dissolve and for patients to absorb.

Purdue University scientist Yuan Yao’s laboratory has developed a solution, a plant-based, highly potent nanoparticle called OHPP (octenylsuccinate hydroxypropyl phytoglycogen) that can solubilize and enable niclosamide. Niclosamide’s solubility can be increased more than 5,000 times with OHPP, and the drug is effectively released to cells. Those findings were published in the International Journal of Pharmaceutics in 2018.

“Niclosamide has a tough, crystalline structure. When given to the human body, it may behave like sand, not effectively releasing the compound to provide therapeutic effects,” said Yao, an associate professor in the Department of Food Science. “But using OHPP, we can solubilize these crystals, potentially making niclosamide bioavailable as a drug for COVID-19.”

Published research showed that in the laboratory the antiviral effect of niclosamide was much greater than that of chloroquine, remdesivir, or lopinavir — other drugs being considered to fight the COVID-19 pandemic. But solving the solubility issue is key to making niclosamide a real option.

Six years ago, Yao’s lab chose niclosamide as a model drug to develop OHPP because of its anti-cancer potential and because it’s one of the most difficult drugs to solubilize. That work could significantly shorten the timeline of getting an effective version of niclosamide on the market if proven an effective treatment for SARS-CoV-2.

“Repositioning of FDA-approved drugs has been a big effort in pharmaceutical research. Now people are looking at niclosamide with a hope to save many lives from the pandemic,” Yao said. “We were interested in niclosamide as a potential anti-cancer drug, but now we are all thrilled by the fact that OHPP-enabled niclosamide can be potentially used to fight COVID-19.”

Yao’s research tested OHPP-developed niclosamide against the drug alone and the drug treated with other commercially available solubilizers. The OHPP formulation was over 5,000 times more soluble than niclosamide alone and 50 times more powerful than the leading commercial solubilizers.

OHPP is made from U.S.-grown corn and is patented at Purdue. In the past decade, Yao has been a global leader in the research and development of plant-based dendrimer-like biomaterials, including OHPP. His team uses food industry methods to create most of these new biomaterials.

“Safety is the first thing we consider when designing a new biomaterial,” he said.

Yao co-founded a startup company, Phytoption LLC, in the Purdue Research Park. The company is now looking for strategic partners to advance OHPP-enabled niclosamide formulations and join the global efforts against COVID-19.

“We are fortunate that we have a platform technology ready for the formulation of niclosamide, which is based on years of time and effort, along with the support from the National Science Foundation, and many organizations in Indiana,” Phytoption CEO Joanne Zhang said. “The COVID-19 pandemic presents an urgent need to assemble a strategic team and bring the technology to the market. If you are interested, let’s collaborate and fight this pandemic together.” 

Featured Stories

Zach Feiner holds a striped bass; Feiner holds a black crappie; Feiner holds his Outstanding Young Alumni Award plaque
Meet Zachary Feiner: 2025 Outstanding Young Alumni Award Winner

Zachary Feiner, who earned his PhD from FNR in 2015 and spent two additional years in West...

Read More
Purdue celebrates 75 year collaboration with UFV
Purdue and Viçosa celebrate 75 years of agricultural partnership

In 1951, Purdue University faculty members traveled more than 4,000 miles from West Lafayette,...

Read More
Gloria's view looking for elk in the south unit of Theodore Roosevelt National Park; two of the many prairie dogs at the park; Gloria welding for the first time.
FNR Field Report: Gloria Aichinger

Sophomore wildlife major Gloria Aichinger spent her summer as a seasonal laborer at Theodore...

Read More
A woman stands in a greenhouse, surrounded by greenery and natural light.
Catalyzing metabolite research for agriculture, ecosystems and industry

Concealed within the molecular machinery of petunia flowers are metabolic, genetic and cellular...

Read More
A spotted eagle ray; Morgan Hamilton snorkeling during a biodiversity survey in Turks and Caicos; Hamilton with a group of students from her study abroad cohort.
FNR Field Report: Morgan Hamilton

Senior aquatic sciences major Morgan Hamilton took her skills and interests on the road for a...

Read More
Presence of multiple ear rots and premature kernel sprouting (e.g., vivipary) on ears which were completely submerged in flood water in East-Central Indiana (right three ears) in comparison to ears in the same field that were not submerged (left three ears)
Risk & Mycotoxin Management in Indiana Corn

Risk & Mycotoxin Management in Indiana Corn

Read More